Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Françoise Bridey"'
Autor:
Françoise Bridey, Claude Négrier, Cedric Duval, Robert Ariëns, Philippe de Moerloose, Alessandro Casini
Publikováno v:
Haematologica, Vol 104, Iss 3 (2019)
Externí odkaz:
https://doaj.org/article/0ac9bbc14b2142369f37582df1e173f1
Autor:
Jerzy Windyga, Benoît Guillet, Lucia Rugeri, Alexandra Fournel, Ewa Stefanska-Windyga, Valérie Chamouard, Sonia Pujol, Céline Henriet, Françoise Bridey, Claude Négrier
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis, 2022, 122 (8), pp.1304-1313. ⟨10.1055/a-1865-6978⟩
Thrombosis and Haemostasis, 2022, 122 (8), pp.1304-1313. ⟨10.1055/a-1865-6978⟩
Background A plasma-derived factor VIII product (pdFVIII; Factane 100 or 200 IU/mL) and a plasma-derived von Willebrand factor product (pdVWF; Wilfactin 100 IU/mL) are approved for replacement therapy by intravenous bolus injections in hemophilia A (
Publikováno v:
Hématologie. 27:232-241
Autor:
Olivier Roumanie, Jennifer Lamazure, Céline Henriet, Françoise Bridey, Eliane Fuseau, Malika Barthez-Toullec, Anne Bellon, Amel Dahmane, Dominique Golly, Wil Stevens
Publikováno v:
British Journal of Clinical Pharmacology
AIMS The pharmacokinetics (PK) of a triple-secured fibrinogen concentrate (FC) was assessed in patients ≥40 kg by noncompartmental analysis over a period of 14 days with multiple blood samples. Limited PK time point assessments in children lead to
Autor:
Emna, Gouider, Anna, Klukowska, Philip, Maes, Helen, Platokouki, Sonia, Pujol, Céline, Henriet, Françoise, Bridey, Jenny, Goudemand
Publikováno v:
Blood Transfus
BACKGROUND: Plasma-derived von Willebrand factor (VWF) (Wilfactin(®), LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults and adolescents with von Willebrand disease (VWD). Replacement therapy in paediatric patien
Autor:
Amel Dahmane, Mohamed El Khorassani, Céline Henriet, Claudia Djambas Khayat, Sonia Pujol, Philippe de Moerloose, Françoise Bridey, Selin Aytac, Annie Harroche
Publikováno v:
Thrombosis and haemostasis. 120(6)
Objective To date, the use of a fibrinogen concentrate (FC) administered in children with inherited fibrinogen deficiency is poorly documented. Treatment modalities may differ from those of adults. The aim of this study was to investigate the pharmac
Autor:
Philippe de Moerloose, Alessandro Casini, Françoise Bridey, Cédric Duval, Claude Negrier, Robert A. S. Ariëns
Publikováno v:
Haematologica, Vol. 104, No 3 (2019) pp. e111-e113
Autor:
Claudia Djambas Khayat, Mohamed El Khorassani, Thierry Lambert, Valérie Gay, Malika Barthez‐Toullec, Jennifer Lamazure, Anne Bellon, Céline Henriet, Françoise Bridey, Claude Négrier
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 17(4)
Essentials A novel fibrinogen concentrate was evaluated in patients with congenital fibrinogen deficiency. An open-label, phase 2-3 trial studied pharmacology, efficacy, and safety in patients >6 years. The product offers safe and effective therapy i